Skip to main content
PLSE logo
PLSE
(NASDAQ)
Pulse Biosciences, Inc.
$26.09-- (--)
Loading... - Market loading

Pulse Biosciences (PLSE) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Pulse Biosciences, Inc.
PLSENasdaq Stock Market

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Company Information

CEOPaul LaViolette
Founded2014
Employees116
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Phone510-906-4600
Address
601 Brickell Key Drive Miami, Florida 33131 United States

Corporate Identifiers

CUSIP74587B101
ISINUS74587B1017
SIC3845

Leadership Team & Key Executives

Paul LaViolette
Chief Executive Officer
Jon Skinner
Chief Financial Officer
Liane Teplitsky
Chief Operating Officer